Press Release
Dec 15, 2015
Neem raises further shareholder capital

Neem Biotech raised significant further funding from its existing shareholders this month. Neem's continued pipeline development will benefit from this funding, including its proposed first in man trial of its lead compound NX-AS-401.This round of funding is now fully subscribed by its shareholders.